Content Spotlight
Podcast: Sustainability equals efficiency, says eXmoor
eXmoor Pharma discusses the steps taken to build a more sustainable facility, the importance of its design, and calls for industry to share advice and initiatives.
Approximately 20% of bioreactor runs over 30 months were rejected due to contamination issues at Sanofi’s Framingham biologics facility, according to the US FDA.
Deal-Making
The companies will rely on AskBio’s Pro10 manufacturing platform to target retinal degeneration.
Lonza joins the race for weight loss drugs with plans to produce an active pharmaceutical ingredient (API) for Iconovo’s intranasal biologic.
Facilities & Capacity
Sartorius and McMaster University have opened a 1,600 square-foot bioprocess research facility in Hamilton, Ontario, about 38 miles south of Toronto.
With the graft-versus-host disease (GVHD) drug available in the US, the company and its partner Syndax prepare for a robust commercial launch.
Global Markets
Contract development and manufacturing organization (CDMO) Samsung Biologics will provide manufacturing services for the client in what it calls its ‘largest ever contract’.
Indian CDMO Aragen has laid out aggressive expansion plans for capacity and multi-modality services following a $100 million investment from Singapore-based private equity (PE) fund Quadria Capital.
Regulations
Approximately 20% of bioreactor runs over 30 months were rejected due to contamination issues at Sanofi’s Framingham biologics facility, according to the US FDA.
With BIOSECURE in limbo, the US government seeks other ways to protect American interests.
Content Spotlight
eXmoor Pharma discusses the steps taken to build a more sustainable facility, the importance of its design, and calls for industry to share advice and initiatives.
Therapeutic Class
The companies will rely on AskBio’s Pro10 manufacturing platform to target retinal degeneration.
BioProcess Insider is back with a Gen Z twist, breaking down 2025’s hottest bioprocessing trends – because the future of CGTs and GLP-1s is straight fire.
Upstream & Downstream Processing
Sartorius and McMaster University have opened a 1,600 square-foot bioprocess research facility in Hamilton, Ontario, about 38 miles south of Toronto.
With the graft-versus-host disease (GVHD) drug available in the US, the company and its partner Syndax prepare for a robust commercial launch.